NCT03309150View on ClinicalTrials.gov

ATRi Transition Rollover Study

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

January 26, 2024

Study Completion Date

January 26, 2024

Conditions
Advanced Stage Solid Tumors
Interventions
DRUG

Berzosertib

Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred.

Trial Locations (1)

Unknown

Royal Marsden NHS Foundation Trust, Sutton

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03309150 - ATRi Transition Rollover Study | Biotech Hunter | Biotech Hunter